NEW YORK. Aug. 24 – DNAPrint Genomics and scientific developer Pharsight have entered into a collaboration to empower DNAPrint’s pharmacogenomic product development, the company announced on Friday.

The terms of the contract, which is open-ended, call for Mountain View, Calif.-based Pharsight to provide DNAPrint with clinically phenotyped DNA specimens from patients who are taking medications known to elicit variable efficacy.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.